Article Text

Download PDFPDF
Randomised controlled trial
High-sensitivity troponin predicts coronary disease outcomes in type 2 diabetes but yields no benefit in selecting patients for revascularisation
  1. Juhani Junttila
  1. Medical Research Center Oulu, University of Oulu and Oulu University Hospital, Oulu, Finland
  1. Correspondence to : Dr Juhani Junttila, Medical Research Center Oulu, University of Oulu and Oulu University Hospital, PO Box 5000, Oulu 90014, Finland; juhani.junttila{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMed


High-sensitivity troponin (hs-TnT) assays have been developed for early recognition of patients with acute coronary syndrome (ACS). Additionally, hs-TnT has been shown to be a feasible tool for assessing risk among patients with heart failure. Even though efforts have been made to improve prognosis among patients with coronary artery disease (CAD) with high-risk features, most adverse events occur in patients without these features. Therefore, novel risk markers for ‘intermediate risk’ participants are needed. Recent evidence presents hs-TnT as a promising marker for adverse events among patients with stable CAD.1 ,2 The pathophysiological background for these findings and therapeutic …

View Full Text


  • Contributors JJ drafted the manuscript of this commentary.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.